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Abstract
Background: As a key gene in the immunosurveillance of cell malignancy, Cytotoxic T-lymphocyte antigen 4
(CTLA-4 is an important negative regulator of T cell activation and proliferation. The CTLA-4 +49G > A
polymorphism is one of the most commonly studied polymorphisms in this gene due to its association with
cancer risks, but previous results have been conflicting.
Methods: We preformed a meta-analysis using 22 eligible case-control studies (including 32 datasets) with a total
of 11,273 patients and 13,179 controls to summarize the existing data on the association between the CTLA-4
+49G > A polymorphism and cancer risk.
Results: Compared with the common CTLA-4 +49G > A GG genotype, the carriers of variant genotypes (CTLA-4
+49 GC/CC) had a 1.24-fold elevated risk of cancer (95% CI = 1.18-1.32, P < 0.05) under the dominant genetic
model, as estimated using a fixed effect model. The effect of the CTLA-4 +49G > A polymorphism was further
evaluated using stratification analysis. In four breast cancer studies, patients with the variant genotypes had a
significantly increased risk of breast cancer (OR = 1.31, 95% CI = 1.17-1.48, P < 0.00001). A similar result was found
in three skin cancer studies (OR = 1.30, 95% CI = 1.10-1.52, P = 0.001). In 26 solid tumor studies, subjects with the
variant genotypes had a significantly higher risk of developing solid tumors (OR = 1.25, 95% CI = 1.18-1.33, P <
0.00001) compared with the 6 non-solid tumor studies (OR = 1.08, 95% CI = 0.79-1.48, P = 0.62). Patients with
variant genotypes had significantly increased risk of non-epithelial tumors and epithelial tumors, with ORs of 1.23
(95% CI = 1.14-1.32, P < 0.00001) and 1.29 (95% CI = 1.17-1.41, P < 0.00001), respectively. It was also demonstrated
that the increased risk of cancer associated with CTLA-4 +49G > A variant genotypes was more pronounced in
Caucasians (OR = 1.29, 95% CI = 1.13-1.47, P = 0.0002), Asians (OR = 1.23, 95% CI = 1.16-1.32, P < 0.00001) and
Chinese (OR = 1.23, 95% CI = 1.15-1.31, P < 0.00001).
Conclusion: Our meta-analysis suggests that the CTLA-4 +49G > A polymorphism genotypes (GA + AA) might be
associated with an increased risk of cancer, especially in Caucasians and Chinese.
Background
The human body generates an immune response to
tumors, but it is generally ineffective at causing tumor
destruction. One possible reason is that T-cell activation
will not occur until two separate signals are received by
the cell. The first signal is specific antigen-recognition,
which requires T-cell receptors to recognize and bind to
major histocompatibility complex (MHC) molecules of
antigen-presenting cells (APCs). The second signal is
nonspecific and antigen-independent, generated by the
interaction between CD28 on the T-cell surface and its
ligands CD80 and CD86 on the APCs [1-4]. The CD28
costimulatory pathway plays a critical role in the induc-
tion and regulation of autoreactive T-cells. Cytotoxic
T-lymphocyte antigen 4 (CTLA-4), a CD28 homologue,
is a glycoprotein expressed on activated T-cells that has
a high binding affinity with the molecule B7, primarily
expressed on APCs [5-8]. Though CTLA-4 shares the
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any medium, provided the original work is properly cited.same costimulatory ligands as CD28, it delivers a differ-
ent costimulatory signal. While CTLA-4 is a well docu-
mented T-cell negative regulator [3], the underlying
molecular basis of its signaling is poorly understood.
A large body of evidence supports the hypothesis that
CTLA-4 may down-regulate T-cell responses [9-11].
Moreover, the majority of cancer cells either have low
immunogenicity, lack costimulatory molecules, or both
[12,13]. Therefore, CTLA-4 may contribute to NPC
development by controlling an individual’si m m u n e
response.
An A®G dimorphism at position 49 in CTLA-4 exon
1 (rs231775) has been reported by Nistico [14], which
causes an amino acid change (threonine to alanine) in
the peptide leader sequence of the CTLA-4 protein [15].
Recent studies found that this polymorphism may influ-
ence the ability of CTLA-4 to bind with B7.1 and subse-
quently, may affect T-cell activation [16,17]. These
results suggest that a G allele instead of an A allele at
position +49 can attenuate the CTLA-4-driven down-reg-
ulation of T-cell responses [16,18,19]. However, the results
of studies on the association between the +49 A > G
polymorphism and the risk of cancers have been
conflicting. So in order to summarize and clarify the
published data we have performed a meta-analysis, using
all eligible case-control studies to assess the association
between the CTLA-4 +49 A > G polymorphism and
cancer risk.
Methods
Identification and Eligibility of Relevant Studies
We carried out a literature search using the PubMed
database (between January 2000 and February 2010) to
identify all papers that investigated the association
between the CTLA-4 +49 A > G polymorphism and
cancer risk in all ethnic groups, using combinations of
the search phrases “CTLA-4 and polymorphism and
cancer”. We evaluated the titles and abstracts of all rele-
vant publications, but excluded abstracts, case reports,
editorials, and review articles. Studies included in the
current meta-analysis had to meet the following criteria:
the study must have used a case-control study design;
the report must have included cancer diagnoses and
sources for the cases and controls; the report must have
included genotype frequencies; the authors must have
given size of their samples, the odds ratios (Ors) used,
and their 95% confidence intervals (CIs); definitions of
exposure or risk genotypes must have been similar in all
reports; and the methods of data collection and analysis
must have been statistically acceptable.
Data extraction and stratification
Data were collected on the CTLA-4 +49 A > G geno-
type from studies of different types of cancer. The first
author, year of publication, country, ethnicity of the
study population, the number of cases and controls, and
the type of study were described (Table 1). In the strati-
fication analyses for ethnicity, there were: 7 Caucasian
populations, including Spanish, Polish, German, Ameri-
can, Sardinian, Macedonian and Italian, and 3 Asian
populations, including Chinese (containing Taiwanese),
Trukese, and Irani. In the stratification analyses for can-
cer type, we compared epithelial tumors to non-epithelial
tumors, and solid tumors to non-solid tumors. There
were 12 types of solid tumors, including those caused
by renal cell cancer, colon carcinoma, cervical squamous
cell carcinoma, breast cancer, lung cancer, esophageal
cancer, gastric cancer, oral squamous cell carcinoma,
thymoma, nasopharyngeal carcinoma, HBV-related
HCC and melanoma. There were 3 types of non-solid
tumors, including those caused by CLL, non-Hodgkin’s
lymphoma and MALT lymphoma. The 4 types of
epithelial tumors were those caused by oral squamous
cell carcinoma, cervical squamous cell carcinoma, mel-
anoma, and breast cancer. The 8 non-epithelial tumors
included those caused by gastric cancer, colon carci-
noma, HBV-related HCC, nasopharyngeal carcinoma,
thymoma, renal cell cancer, lung cancer and esopha-
geal cancer.
Methods for quantitative synthesis
The selection of published studies we used for meta-
analysis were further evaluated using sensitivity analyses.
Odds ratios (ORs) and 95% confident interval (CIs)
from each case-control study were used to assess the
strength of association between the CTLA-4 +49A > G
genotypes and the risk of cancer in dominant (GA+AA
vs GG) genetic models. A combined OR was calculated
according to Woolf’s method [20]. A c2-based Q statistic
test was performed to assess between-study heteroge-
neity [21]. If the P value of the heterogeneity test was
≥ 0.05, then a fixed effect model using the Mantel-
Haenszel method was used to calculate the combined
OR, which assumed the same homogeneity of effect
size across all studies. If the P value of the heterogene-
ity test was <0.05, it showed that the between-study
heterogeneity was statistically significant. A random
effects model, using the DerSimonian and Laird
method, was performed to calculate the combined OR
[22]. If there were no between-study heterogeneity, the
combined OR calculated by those two methods would
be identical. The significance of the combined OR was
determined using a Z-test, in which P < 0.05 was con-
sidered significant. Finally, the combined ORs and
their 95% CIs were presented. Stratification analyses
for different types of cancers were conducted for color-
ectal cancer, breast cancer, gastric cancer, lymphoma, skin
cancer, and other cancers (lung cancer, nasopharyngeal
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First author
(year)
Case
no.
Control
no.
Ethnicity Country Cancer type Matched variables Type of study
Cozar (2007) 125 176 Caucasian Spain Renal Cell Cancer Age, sex, and residence
area matched
Hospital-based
Cozar (2007) 96 176 Spanish Spain Colon Carcinoma Ethnically matched Hostipal-based
Su (2007) 139 375 Taiwanese
Women
China Cervical Squamous Cell
Carcinoma
Age and sex matched Hostipal-based
Pavkovic
(2003)
30 100 Caucasians Macedonia CLL (+)AIHA Age, sex, and residence area
matched
Hospital-based
Pavkovic
(2003)
100 100 Caucasians Macedonia CLL (-)AIHA Age, sex, and residence area
matched
Hospital-based
Suwalska
(2008)
170 224 Polish Poland B-CLL Age and sex matched Hospital-based
Wang (2007) 117 148 Han people China Breast Cancer Age matched Hospital-based
Bouwhuis
(2009)
762 734 German Germany Malignant Melanoma Age matched Hostipal-based
Sun (2008) 1163 1132 Han people China Lung Cancer (Beijing) Aex matched Hospital-based
Sun (2008) 1032 1021 Han people china Lung Cancer(Jiangsu) Age-sex and residential area
matched
Hospital-based
Sun (2008) 1060 1070 Han people China Breast Cancer (Beijing) Age-sex and residential area
matched
Hospital-based
Sun (2008) 1037 1070 Han people China Breast Cancer (Jiangsu) Age-sex and residential area
matched
Hospital-based
Sun (2008) 1010 1008 Han people China Esophagus Cancer (Beijing) Age-sex and residential area
matched
Hospital-based
Sun (2008) 530 530 Han people China Gastric Cardia Cancer
(Beijing)
Age-sex and residential area
matched
Hospital-based
Hou (2010) 205 262 Han people China Gastric Cancer
Dilmec (2008) 56 162 Trukese Turkey Colorectal Cancer Age, sex and ethnically
matched
Hostipal-based
Welsh (2009) 897 819 New Hampshire
people
American Non-melanoma Skin
Cancer BCC
Age and sex matched Hospital-based
Welsh (2009) 684 819 New Hampshire
People
American Non-melanoma Skin
Cancer SCC
Age, sex, and residence area
matched
Hospital-based
Hadinia (2007) 105 190 Irani Iran Colorectal Cancer Hostipal-based
Hadinia (2007) 43 190 Irani Iran Gastric Cancer Age and sex matched Hostipal-based
Wong (2006) 118 147 Taiwan People China Oral Squamous Cell
Carcinoma
Age and sex matched Hostipal-based
Piras (2005) 100 128 Sardinia People Sardinia Non-Hodgkin’s Lymphoma Sex matched
Ghaderi (2004) 197 151 Iranian Women Iran Breast Cancer Age matched Hostipal-based
Qi (2010) 124 407 Chinese China Colorectal Cancer Age and sex matched
Cheng (2006) 62 250 Han Chinese China MALT Lymphoma Age and sex matched
Solerio (2005) 186 238 Caucasian Italian Colorectal Adenomas Age, sex, and residence area
matched
Hospital-based
Solerio (2005) 132 238 Caucasian Italian Colorectal Cancers Age and sex matched
Monne (2004) 44 76 Caucasian Italy Non-Hodgkin’s
Lymphomas(NHL)
Age and sex matched Hospital-based
Chuang (2005) 79 173 White Germans Germany Myasthenia gravis MG(+)
Thymoma
Hospital-based
Chuang (2005) 46 173 White Germans Germany Myasthenia gravis MG(-)
Thymoma
Hospital-based
Xiao (2009) 457 485 Han Chinese China Nasopharyngeal Carcinoma Age and sex matched Hospital-based
Gu (2010) 367 407 Han Chinese China HBV-related HCC Hospital-based
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geal cancer, oral squamous cell carcinoma, HBV-
related hepatocellular carcinoma or renal cell cancer)
to estimate cancer-specific ORs. Stratification analyses
by ethnicity were also conducted for Caucasian, Chi-
nese and other Asian race populations to estimate eth-
nicity-specific ORs. Publication bias was assessed using
a funnel plot, in which the standard error of log (OR)
of each study was plotted against its OR value. The
resulting asymmetrical plot suggested, according to
Egger’s linear regression test, that there was possible
publication bias [23]. The significance of the intercept
was determined using a Student t-test, as suggested by
Egger. If the P-value of Egger’s linear regression test
was less than 0.05, it meant that there was a publica-
tion bias in the meta-analysis. The SAS/Genetics soft-
ware program (Version 9.1, SAS Institute, Inc., Cary,
NC, USA) was used to determine the LD of SNP pairs
and the Hardy-Weinberg equilibrium. Other statistical
software used included SPSS12.0 for Windows (SPSS
Inc., Chicago, USA), Stata Version 10.0, and Review
Manager (Version 4.2, the Cochrane Collaboration). All
P-values were two-sided.
Results
Literature search and meta-analysis databases
We searched NCBI PubMed using the key terms ‘CTLA-
4’‘ cancer’ and ‘polymorphism’ and found 36 epidemio-
logical studies. Of these 36 studies, 14 studies were
excluded either because they were not case-control stu-
dies or because the +49A/G polymorphism or its geno-
type frequency was not reported. The remaining 22
case-control studies contained 32 data sets (Sun’ss t u d y
had six datasets, and Pavkovic’s, Welsh’s, Hadinia’s,
Solerio’s, and Chuang’s studies all had two datasets
each) [16,24-28]. We created a database of the informa-
tion extracted from each article. The essential informa-
tion, including first author, cancer type, year of
publication, numbers of cases and controls, and the fre-
quencies of CTLA-4 +49A/G for all studies are listed in
Table 1. There were four studies concerning breast cancer
[16,17,29], six concerning colorectal cancer [25,27,30-32],
six concerning non-solid tumors [26,33-36], three con-
cerning gastric cancer [16,25,37], three concerning skin
cancer [28,38], two concerning Thymoma [24], two con-
cerning lung cancer [16], one concerning nasopharyngeal
carcinoma [39], one concerning cervical squamous cell
carcinoma [40], one concerning Esophagus cancer [16],
one concerning Oral squamous cell carcinoma [41], one
concerning HBV-related hepatocellular carcinoma [42],
and one concerning renal cell cancer [30]. Among the 32
datasets included in the final analysis, there were 14
concerning Caucasians and 18 concerning Asians (14 con-
cerning Chinese, one concerning Trukese and three
concerning Irani). Additional information is listed in the
forest plots in our meta-analyses. We performed a sensi-
tivity analysis on the selection of published studies in this
meta-analysis.
Test for heterogeneity
The results of our Q test show that there was no
between-study heterogeneity in the dominant genetic
models (GA+AA VS GG) for all 32 datasets (P =0 . 1 2 ) .
In the subgroup analyses for cancer type and ethnicity
(results shown in Figures 1, 2, 3, 4 and 5), the heteroge-
neity test did not reveal any significant differences
between the dominant genetic models (GA+AA VS
GG): six colorectal cancer studies (P = 0.40), four breast
cancer studies (P = 0.11), six non-solid tumor studies
(P = 0.23), three skin cancer studies (P = 0.30) (Figure 1),
and twenty-six solid tumor studies (P=0.15) (Figure 3),
seventeen non-epithelial tumor studies (P =0 . 1 6 ) ,n i n e
epithelial tumor studies (P = 0.25) (Figure 5), fourteen
Caucasian population studies (P = 0.51), fourteen
Chinese population studies (P = 0.13), and eighteen
Asian studies (P = 0.05) (Figure 2 and 4). However, the
results of our heterogeneity test did indicate significant
differences (P = 0.01) for gastric cancer (Figure 1).
Quantitative data synthesis
For the CTLA-4 +49G > A polymorphism, we obtained
our meta-analysis data from 32 datasets consisting of
11,273 cases and 13,179 controls. The associations
between the CTLA-4 +49G > A genotype and cancer
risks were estimated using dominant (GA+AA vs GG)
genetic models in either fixed or random effect models
according to the heterogeneity Q test. We used 32
datasets in these comparisons. Compared with the
wild-type +49G > A GG genotype, the carriers of var-
i a n tg e n o t y p e s( G A / A A )h a da1 . 2 4 - f o l de l e v a t e dr i s k
of cancer (95% CI = 1.18-1.32, P< 0.05) as estimated
by a fixed effect model for dominant genetic effects
(Figure 6).
The effect of the CTLA-4 +49G > A polymorphism
was further evaluated using stratification analysis. In the
six colorectal cancer studies, which included 699 cases
and 1,411 controls, subjects with variant genotypes (597
cases and 1,144 controls) had a non-significant increased
risk of colorectal cancer (OR = 1.03, 95% CI = 0.78-1.35,
P = 0.86) as estimated using a fixed effect model (Figure 1).
Similar results were found in the three gastric cancer
studies, with 778 cases and 982 controls (OR = 1.17,
95% CI = 0.96-1.43, P = 0.12), and the six non solid
tumour studies, with 506 cases and 878 controls (OR
= 1.08, 95% CI = 0.79-1.48, P = 0.62) (Figure 1). How-
ever, in the four breast cancer studies, consisting of
2,411 cases and 2,439 controls, the variant genotypes
(1,436 cases and 1,292 controls) were associated with a
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95% CI = 1.17-1.48, P < 0.00001) (Figure 1). Similar
results were found in the three skin cancer studies,
which included 2,342 cases and 2,372 controls (OR =
1.30, 95% CI = 1.10-1.52, P =0 . 0 0 1 ) ,a n di nt h e2 6
solid tumour studies, which had 10,767 cases and
12,301 controls (OR = 1.25, 95% CI = 1.18-1.33, P <
0.00001) (Figure 1 and 3). We also found that patients
with the variant genotypes had significantly increased
risks for developing either non-epithelial tumors or
epithelial tumors, with ORs of 1.23 (95% CI = 1.14-
1.32, P < 0.00001) and 1.29 (95% CI = 1.17-1.41, P <
0.00001), respectively (Figure 5).
In the stratification analyses for ethnicity, we found
that the increased risk of cancer associated with +49G >
A variant genotypes was more pronounced in Cauca-
sians (OR = 1.29, 95% CI = 1.13-1.47, P = 0.0002),
Asians (OR = 1.23, 95% CI = 1.16-1.32, P < 0.00001),
and Chinese (OR = 1.23, 95% CI = 1.15-1.31, P <
0.00001) (Figure 2 and 4).
Figure 1 Meta-analysis for CTLA-4 +49G > A polymorphism variant genotypes GA + AA vs. GG in different type of cancers.
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To evaluate publication bias, the CTLA-4 +49G > A
genotypes were plotted against the precision ones using
a funnel plot. The result was approximately symmetrical,
so Egger’s test suggests that there is no publication bias
in the current meta-analysis (P = 0.998). This indicates
that biases from publications and other factors may not
have had a significant influence on the results of our
meta-analysis on the association between CTLA-4 +49G >
A polymorphism and cancer risk (Figure 7).
Discussion and Conclusions
In this meta-analysis, which includes 22 independent
case-control studies with 32 data sets, we found that the
carriers of the CTLA-4 +49 (GA+AA) variant genotypes
had a 1.24-fold increased risk of cancer in the dominant
genetic model. These results support the hypothesis that
polymorphisms of CTLA-4 play an important role in
the development of cancer. However, we did not find
evidence of significant associations in subgroup analyses
for individual types of cancers, such as colorectal cancer,
gastric cancer and non-solid tumors.
The immune system is a complex network that has
evolved to protect humans against infectious agents and
tumor growth. T-cells and natural killer (NK) cells are
the major anti-tumor factors. Given that the activation of
T-cells requires two signals, the CD28 costimulatory
pathway has been shown to play a critical role in the
induction and regulation of autoreactive T-cells. Further-
more, the human CTLA4 and CD28 genes are located
Figure 2 Meta-analysis for CTLA-4 CTLA-4 +49G > A polymorphism variant genotypes GA + AA vs. GG in different ethnicities.
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and separated by only 130 kb [43]. The gene structure
of CTLA4 is very similar to that of CD28, except for
3’ and 5’ flanking sequences. All these data suggest
that CTLA-4 and CD28 may be members of the same
pathway, but execute different functions. Several
groups found that CTLA-4 binds to the same ligands
as CD28, i.e. CD80 and CD86 molecules, but has at
least a 20-fold greater affinity [44]. In contrast to
CD28, CTLA-4 does not provide a positive signal for
Figure 3 CTLA-4 +49G > A polymorphism variant genotypes GA + AA vs. GG in Solid tumor.
Figure 4 CTLA-4 +49G > A polymorphism variant genotypes GA + AA vs. GG in Chinese.
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Page 7 of 11T-cell activation. Thus, CTLA-4 may contribute to the
down-regulation of anti-tumor immune responses via
interference with the CD28 costimulatory pathway.
Moreover, CTLA-4 has been reported to increase TGF
production, engage negative signaling pathways, inhibit
lipid-raft and disturb TCR-induced stop signals
[11,45,46]. Nistico and his colleagues reported a func-
tional polymorphism in CTLA4 exon 1 which causes a
threonine to alanine amino acid exchange in this pro-
tein’sl e a d e rs e q u e n c e[ 1 4 ] .W en o t e dt h ei m p a c to f
the CTLA4 exon 1 + 49 A/G dimorphism on immune
regulation after T-cell stimulation. Several studies
found that the surface expression and intracellular dis-
tribution of CTLA-4 differ between the two genotypes
[18,19]. Results of the T-cell proliferation and B7.1
binding capability studies by Sun et al. suggest that
the G allele at this position is correlated with increased
T-cell activation [16].
This study evaluated the associations of CTLA-4
+49A/G polymorphisms with different cancers. We
found that this polymorphism was associated with an
increased risk of developing solid tumors (including
lung caner, breast cancer, colorectal cancer, gastric
cancer, skin cancer, thymoma, nasopharyngeal carci-
noma, cervical squamous cell carcinoma, esophageal
cancer, oral squamous cell carcinoma, HBV-related
hepatocellular carcinoma, and renal cell cancer), but
not non-solid tumors, suggesting that the CTLA-4
gene plays different roles in the carcinogenesis of these
two types of tumors. In our stratified analysis for eth-
nicity, the CTLA-4 +49G > A variant genotypes (GA +
AA) were associated with an increased risk of cancer
in Caucasians (OR = 1.29, 95% CI = 1.13-1.47, P =
0.0002), Chinese (OR = 1.23, 95% CI = 1.15-1.31, P <
0.00001), and Asians (OR = 1.23, 95% CI = 1.16-1.32,
P < 0.00001), suggesting that the different genetic
Figure 5 CTLA-4 +49G > A polymorphism variant genotypes GA + AA vs. GG in epithelial and non-epithelial tumors.
Zheng et al. BMC Cancer 2010, 10:522
http://www.biomedcentral.com/1471-2407/10/522
Page 8 of 11backgrounds of the different populations may to some
extent explain the different risk estimates associated
with the variant CTLA-4 genotypes. It seems that cer-
tain populations may have a higher susceptibility to
cancer because they have higher frequencies of the var-
iant genotypes +49G > A (GA + AA). Potential publi-
cation biases may exist in this meta-analysis, because
studies with negative results are less likely to be pub-
lished. Because only four out of 32 datasets were popu-
lation-based case-control studies, with the others being
hospital-based case-control studies, the study subjects
may also not be representative of the general popula-
tion. This could lead to selection bias.
In conclusion, our meta-analysis found evidence for an
association between CTLA-4 +49A/G polymorphisms and
multiple cancers in the general population, particularly for
solid tumors. Due to the limitations of meta-analyses,
larger association studies or multi-centric case-control
studies are needed to confirm these findings.
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